Compare KTTA & PRZO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KTTA | PRZO |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1M | 17.5M |
| IPO Year | 2021 | 2022 |
| Metric | KTTA | PRZO |
|---|---|---|
| Price | $0.55 | $0.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 216.1K | ★ 2.6M |
| Earning Date | 05-14-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $486,559.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3130.37 | N/A |
| 52 Week Low | $0.28 | $0.38 |
| 52 Week High | $2.06 | $1.90 |
| Indicator | KTTA | PRZO |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 67.16 |
| Support Level | $0.54 | $0.76 |
| Resistance Level | $0.61 | $0.82 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 92.85 | 59.34 |
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
ParaZero Technologies Ltd operates as an aerospace defense company focused on the development of smart, autonomous solutions for the manned and unmanned aerial systems (UAS) industry. The Company develops, manufactures, markets, and sells counter-UAS net-launching platforms designed to protect against hostile drones in both battlefield and urban environments, precision aerial delivery systems for military applications, and smart, autonomous parachute safety systems designed to enable safe flight operations over populated areas and beyond visual line-of-sight. The Company sells its products internationally.